Arbutus Biopharma (NASDAQ:ABUS) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Arbutus Biopharma (NASDAQ:ABUS) from a sell rating to a hold rating in a report released on Monday morning, Zacks.com reports.

According to Zacks, “Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company’s products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC. “

Several other analysts have also issued reports on the company. Echelon Wealth Partners lowered Arbutus Biopharma from a hold rating to a sell rating in a report on Friday, October 4th. B. Riley increased their target price on Arbutus Biopharma from $3.00 to $6.00 and gave the stock a buy rating in a report on Thursday, January 9th. ValuEngine raised Arbutus Biopharma from a hold rating to a buy rating in a report on Friday, January 3rd. Finally, Chardan Capital lowered Arbutus Biopharma from a buy rating to a neutral rating in a report on Friday, October 4th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of $4.25.

ABUS opened at $3.07 on Monday. The firm has a market cap of $186.34 million, a P/E ratio of -3.01 and a beta of 1.99. Arbutus Biopharma has a 52-week low of $0.82 and a 52-week high of $4.75. The company has a debt-to-equity ratio of 0.10, a quick ratio of 10.70 and a current ratio of 10.70. The business’s fifty day moving average is $2.54 and its 200-day moving average is $1.78.

Arbutus Biopharma (NASDAQ:ABUS) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.22). The company had revenue of $3.10 million for the quarter, compared to analyst estimates of $9.85 million. Arbutus Biopharma had a negative return on equity of 298.87% and a negative net margin of 2,416.39%. On average, research analysts predict that Arbutus Biopharma will post -1.22 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in ABUS. Tower Research Capital LLC TRC grew its holdings in shares of Arbutus Biopharma by 710.8% during the 3rd quarter. Tower Research Capital LLC TRC now owns 38,789 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 34,005 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in Arbutus Biopharma by 40.4% in the second quarter. Jacobs Levy Equity Management Inc. now owns 30,593 shares of the biopharmaceutical company’s stock valued at $64,000 after buying an additional 8,797 shares in the last quarter. A.R.T. Advisors LLC acquired a new stake in Arbutus Biopharma in the second quarter valued at about $74,000. Paloma Partners Management Co acquired a new stake in Arbutus Biopharma in the second quarter valued at about $327,000. Finally, Jane Street Group LLC acquired a new stake in Arbutus Biopharma in the second quarter valued at about $348,000. 30.75% of the stock is currently owned by institutional investors.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies.

Recommended Story: What are the benefits of a balanced fund?

Get a free copy of the Zacks research report on Arbutus Biopharma (ABUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.